Navigation Links
Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
Date:3/22/2010

EXTON, Pa., March 22 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer of West Pharmaceutical Services, Inc., has joined Kensey Nash's Board of Directors.

Dr. Morel has served as Chief Executive Officer of West Pharmaceutical Services, Inc. since April 2002 and Chairman of the Board since March 2003.  He joined West in 1992 as Director of Research and Development and was promoted to Vice President R&D in 1993.  In this role, Dr. Morel spearheaded West's efforts to develop novel and proprietary drug delivery technologies. From 1998 to 2001, he served as President of several of West's divisions and in April 2001 Dr. Morel became President and Chief Operating Officer.  

Prior to joining West Pharmaceutical, Dr. Morel developed and managed a broad range of programs involving advanced materials for aerospace, biomedical and pharmaceutical applications for several companies.  Dr. Morel holds a BS degree in Engineering from Lafayette College, an MS in Materials Science and a Ph.D. in Materials Science and Veterinary Medicine from Cornell University.  He has received several awards and honors including becoming a fellow for the American Institute for Medical & Biologic Engineering.  In addition to Kensey Nash's Board, Dr. Morel serves as a Director and Trustee of numerous non-profit organizations including the Fox Chase Cancer Center.

"Dr. Morel's extensive business experience and materials science knowledge will be a tremendous asset to our Board and our company," commented Joseph W. Kaufmann, President and CEO of Kensey Nash Corporation.  "His outstanding leadership as Chairman and CEO of West Pharmaceutical is well documented and we are fortunate to have someone of his stature on our Board.  I am very pleased to welcome him as a member," he concluded.

"Over the past twenty-five years Kensey Nash has developed a broad range of innovative products and materials that have benefited patients worldwide.  I am pleased to have the opportunity to join the Board and look forward to working with the current Directors and talented management team to achieve the company's strategic objectives," Dr. Morel commented.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology.  The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials.  The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including, the cardiology, orthopedic, sports medicine, spine, endovascular and general surgery markets.

SOURCE Kensey Nash Corporation

Back to top

RELATED LINKS
http://www.kenseynash.com

'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kensey Nash Announces IDE Submission for Cartilage Repair Device
2. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
4. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
5. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
6. Kensey Nash Announces $30 Million Share Buyback
7. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
8. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... communities in the greater Dallas, Miami, and Raleigh regions, is organizing an extended ... overcome a rare and deadly chromosome abnormality. , After struggling since birth with ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
Breaking Medicine News(10 mins):